ID | 54508 |
JaLCDOI | |
フルテキストURL | |
著者 |
Wada, Koichiro
Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
ORCID
researchmap
Uehara, Shinya
Department of Urology, Kawasaki Hospital, Kawasaki Medical School
Ishii, Ayano
Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Kaken ID
publons
researchmap
Sadahira, Takuya
Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Yamamoto, Masumi
Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Mitsuhata, Ritsuko
Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Takamoto , Atsushi
Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Araki, Motoo
Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
ORCID
Kaken ID
publons
researchmap
Kobayashi, Yasuyuki
Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
ORCID
Kaken ID
Watanabe, Masami
Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Kaken ID
publons
researchmap
Watanabe, Toyohiko
Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
ORCID
Kaken ID
publons
researchmap
Hotta, Katsuyuki
Center for innovative Clinical Medicine, Okayama University Hospital
Kaken ID
publons
researchmap
Nasu, Yasutomo
Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Kaken ID
publons
researchmap
|
抄録 | Urinary tract infections (UTIs) are the most common bacterial infections in women, and many patients experience frequent recurrence. The aim of this report is to introduce an on-going prospective phase II clinical trial performed to evaluate the preventive effectiveness of Lactobacillus vaginal suppositories for prevention of recurrent cystitis. Patients enrolled in this study are administered vaginal suppositories containing the GAI 98322 strain of Lactobacillus crispatus every 2 days or 3 times a week for one year. The primary endpoint is recurrence of cystitis and the secondary endpoints are adverse events. Recruitment began in December 2013 and target sample size is 20 participants.
|
キーワード | probiotics
lactobacilli
Lactobacillus crispatus
urinary tract infection
vaginal suppository
|
Amo Type | Clinical Study Protocols
|
出版物タイトル |
Acta Medica Okayama
|
発行日 | 2016-08
|
巻 | 70巻
|
号 | 4号
|
出版者 | Okayama University Medical School
|
開始ページ | 299
|
終了ページ | 302
|
ISSN | 0386-300X
|
NCID | AA00508441
|
資料タイプ |
学術雑誌論文
|
言語 |
英語
|
著作権者 | CopyrightⒸ 2016 by Okayama University Medical School
|
論文のバージョン | publisher
|
査読 |
有り
|
PubMed ID | |
Web of Science KeyUT |